Assessment of the side effects of progestogen only contraception in the immediate postpartum period: the case of implants with levonorgestrel Jadelle®

Moussa Diallo, Abdoul Aziz Diouf, Astou Coly Niassy Diallo, Omar Gassama, Alassane Diouf


Background: The aim of this study was to evaluate the side effects of Jadelle® implants in the immediate postpartum.

Methods: To do this, we inserted the implants at two different postpartum period: first, between the first and the seventh day for the immediate postpartum period (IPP) group; second, between the 45th and the 3rd postpartum months for the late postpartum (LPP) group. The variables studied were age, gesture, parity, abortions, number of live children, childbirth, caesarean section, quality of milky climb, age last child, pregnancy-attendant, pregnancy term at time of delivery, complaints, weight.

Results: From May 2012 to December 2013, we collected two hundred patients, one hundred from each group (immediate postpartum and late postpartum). The average age of mothers in the IPP group was 28 years and 29 years for LPP group. After insertion, in both group, spotting were the most frequent complaints. The weight variations were between +800 g and -600 g for the group IPP and +260 g and -170 g for the other group; which makes a statistically significant difference. In both groups, at the end of the six months, no patient had menstruation.

Conclusions: Our results are encouraging to further promote contraception in the immediate postpartum period in developing countries and thus reach a wide range of users. We can therefore say that the side effects are not different during this period and largely are also tolerated.


Contraception progestogen, Immediate postpartum, Implants, Progestogen

Full Text:



ANSD. Agence Nationale de la Statistique et de la Démographie. Enquête Démographique et de Santé Sénégal 2014. EDS continue; 2014.

USAID. Accélérer l'accès à la planification familiale du postpartum (PFPP) en Afrique sub-saharienne et en Asie: Fiche de travail des stratégies de programmation pour la PFPP; 2013.

Wilson S, Tennant C, Sammel MD, Schreiber C. Immediate postpartum etonogestrel implant: a contraception option with long-term continuation. Contraception. 2014;90:259-64.

Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception. 2009;80:113-8.

Meirik O, Brache V, Orawan K, Habib NA, Schmidta J, Ortayli N, et al. A multicenter randomized clinical trial of one-rod etonogestrel and two-rod levonorgestrel contraceptive implants with nonrandomized copper-IUD controls: methodology and insertion data. Contraception. 2013;87:113-20.

Ba M, Moreau JC, Sokal D. A 5-year clinical evaluation of Norplant implants in Senegal. Contraception. 1999;59:377-81.

Shaaban M, Salem H, Abdullah K. Influence of levonorgestrel contraceptive implants, Norplant, initiated early postpartum upon lactation and infant growth. Contraception. 1985;32:623-35.

Harrisa M, Kaneshirob B. An evidence-based approach to hormonal contraception and headaches. Contraception. 2009;80:417-21.

Norplant ICP-MSo. Post-marketing surveillance of Norplant contraceptive implants: II. Non-reproductive health; 2001:187-209.

Bellagio. Consensus Conference on Lactational Infertility. Bellagio Consensus statement on the use of breastfeeding as a family planning method. Contraception. 1989;39(5):477-96.

Coutinho E. One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant). Contraception. 1993;47:97-105.

Zenger E, Qiu S, Fang H. Introduction of Norplant implants in four countries of rural China: a two-year evaluation. Contraception. 1995;52:349-55.

Coutinho EJd, Athayde C. Multicenter clinical trial on the efficacy and acceptability of a single contraceptive implant of nomegestrol acetate, Uniplant. Contraception. 1996;53:121-5.